GGrantIndex
← Search

CHARACTERIZED CELL LINE CORE

$134,422P30FY2013CANIH

University Of Tx Md Anderson Can Ctr, Houston TX

Investigators

Linked publications, trials & patents

Trial NCT07407920Trial NCT07349641Trial NCT06651580Trial NCT05681026Trial NCT05223036Trial NCT05078866Trial NCT05057312Trial NCT05054296Trial NCT05044546Trial NCT05023967Trial NCT05011045Trial NCT04875728Trial NCT04870645Trial NCT04810091Trial NCT04751422Trial NCT04740164Trial NCT04668300Trial NCT04615013Trial NCT04505267Trial NCT04484909Trial NCT04483349Trial NCT04481204Trial NCT04474301Trial NCT04458610Trial NCT04447222Trial NCT04435691Trial NCT04430725Trial NCT04407247Trial NCT04373720Trial NCT04317781Trial NCT04311723Trial NCT04310826Trial NCT04310397Trial NCT04265430Trial NCT04257045Trial NCT04256941Trial NCT04239989Trial NCT04239976Trial NCT04239157Trial NCT04236882Trial NCT04228042Trial NCT04220827Trial NCT04220775Trial NCT04220008Trial NCT04219969Trial NCT04219904Trial NCT04216732Trial NCT04216563Trial NCT04216524Trial NCT04216472Trial NCT04215029Trial NCT04200534Trial NCT04199026Trial NCT04196972Trial NCT04189783Trial NCT04189770Trial NCT04189757Trial NCT04188418Trial NCT04188405Trial NCT04186884Trial NCT04186832Trial NCT04185337Trial NCT04181463Trial NCT04171622Trial NCT04171219Trial NCT04171037Trial NCT04169763Trial NCT04169737Trial NCT04169542Trial NCT04160052Trial NCT04151082Trial NCT04150939Trial NCT04140487Trial NCT04135326Trial NCT04134208Trial NCT04132843Trial NCT04132505Trial NCT04132440Trial NCT04129138Trial NCT04128748Trial NCT04128501Trial NCT04127721Trial NCT04125914Trial NCT04119037Trial NCT04106843Trial NCT04106245Trial NCT04090619Trial NCT04090567Trial NCT04087057Trial NCT04083378Trial NCT04082572Trial NCT04074746Trial NCT04066894Trial NCT04062305Trial NCT04062266Trial NCT04058964Trial NCT04054245Trial NCT04054167Trial NCT04054154Trial NCT04053517

Abstract

. PROJECT SUMMARY (See instructions): The Characterized Cell Line core (CCLC) was established in 2008 with the purpose of preserving and distributing cell lines developed at MD Anderson. The initial focus was on providing well-characterized cell lines so that researchers could choose the correct cell line for their research. Services were expanded almost immediately to include human cell line validation and Mycoplasma testing. Cell line validation is done by short tandem repeats (STR) profiling. To avoid duplicating equipment and effort, the polymerase chain reaction (PCR) fragmentation reactions are run by the Sequencing and Microarray Facility on an Applied Biosystems 3730 XL genetic analyzer. The CCLC has developed a novel STR matching algorithm that can take into account variations due to cell line cross-contamination and to genomic instability. CCLC has also established a proprietary database with STR profiles from over 1000 unique cell lines as well as over 2000 public STR profiles. The CCLC also offers mutational analysis of human cell lines as another method to ensure cell line authenticity. Mutational analysis is done using a Sequenom MassARRAY, which runs a primer extension based method to determine sequence information on a single base. The CCLC has developed a custom somatic mutation panel enabling incorporation of new somatic mutations as they are published in the literature, rather than waiting for a new somatic mutational panel from Sequenom. The CCLC also offers custom-designed panels. Since 2008, the CCLC has been used by 128 Center members, representing all 19 CCSG programs. The institution has supported this core with funding of $99,692 for capital equipment, including incubators, a -80¿ C freezer, PCR machines, a plate reader, and a Qiacube robot. The CCLC has facilitated publication of 53 reports since 2008, with 58% in journals with an impact score >5 and 15% in journals with an impact factor >10. Publications cited using the CCLC have appeared in several high impact journals such as Nat Gen, Cell, Cancer Cell and J Natl Cancer Inst. Peer-reviewed investigators account for 91% of the utilization, and 34% of the total costs are requested from the CCSG. This will enable expansion of services and additional testing of cell lines to identify cross-contamination between species as well as to test for potential virus contamination. Future work will focus on expanding the number of cell lines available to MD Anderson researchers, expanding characterization of cell lines to include whole genome/exome sequencing approaches, and improving methods to detected cross contamination especially intra-species cross-contamination.

View original record on NIH RePORTER →